Quote:

---

Exactly.
Only 3 occurrences will bring about a meaningful increase.

1. Partnership
2. Buyout
3. Approval.

---

Trial results from mssCRC and especially the Alzheimer's pilot study could push the share price nicely. Biopharma investors are always looking for potential and want to get in cheap before a significant share price rise. Alzheimer's on the other hand could get mainstream media coverage and pull in a broader range of investors.